Phase 2 Start
ARGX: Phase 2 Start: A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and T
October 15, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 15, 2026
- Company
- ARGENX SE (ARGX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and T
- Company
- ARGENX SE (ARGX)
- Indication
- Immunoglobulin A Nephropathy (IgAN)